Parkinson's Disease
Purpose of the study: To measure the effects of CVN424 in Parkinson's Disease (PD) participants experiencing motor fluctuations and dyskinesia.
Eligibility inclusion criteria
- Are at least 30 years old.
- Have a confirmed diagnosis of Parkinson's Disease (PD)
- Experience clearly defined ON, OFF, and dyskinetic periods throughout the day where PD medication is either managing symptoms or waning.
- Have been on a stable dose of PD medication for at least 30 days; MOA-B inhibitors (such as selegiline, rasagiline, safinamide) must be stable for 12 weeks.
- Are able to freely move about, with or without an assistive device.
Eligibility exclusion criteria
- Diagnosis of secondary or atypical parkinsonism
- Severe or disabling dyskinesia or OFF expected to preclude successful study participation, in the opinion of the investigator.
- Any previous procedure or therapy designed to provide continuous levodopa or stimulation of dopaminergic tone (i.e. Duopa, apomorphine, subcutaneous levodopa), surgery for PD (i.e. Deep brain stimulation [DBS] or anticipation of these during the study.
- Routine use of PD on-demand medications (i.e., inhaled levodopa, apomorphine injection). Routine use defined as three (3) or more uses per week of on-demand medication is not allowed. On demand medications should only be used for medical emergencies and should be avoided on anticipated diary days, as best as possible.
Sponsor: Cerevance Beta
Purpose of the study: To test whether NEU-411 can help prevent or slow the progression of PD in LRRK2-driven participants, test the safety of NEU-411, determine how your body absorbs, breaks down and removes NEU-411 and determine how long NEU-411 stays in your blood.
Eligibility inclusion criteria
- Age between 40 -80 years.
- Have received a diagnosis of Parkinson's disease by a neurologist.
- Must test positive (LRKK2-driven) using the investigational CDx.
- A screening brain dopamine transporter single-photon emission computed tomography (DaT-SPECT) consistent with PD based on scan performed within 1 year of screening or performed and centrally interpreted during screening.
- No anticipated need for dopaminergic medication to treat PD symptoms for the duration of the trial period.
Eligibility exclusion criteria
- Parkinsonian syndromes due to a secondary etiology or that are unlikely to exhibit clinically meaningful improvement of motor symptoms from dopaminergic medications(levodopa non-responsive), including parkinsonism from encephalitis, metabolic disorders, vascular parkinsonism, drug-induced parkinsonism, multiple system atrophy, corticobasal syndrome, progressive supranuclear palsy, LB dementia.
- Known homozygous carriers of the familial PD genes such as Parkin, phosphatase and tensin homologue-induced kinase 1 (PINK1), protein deglycase-1 (DJ-1 also known as PARK7), synuclein (SNCA), and/or glucocerebrosidase (GBA).
- Participants unable to refrain from or anticipate the use of the medication classes listed prior to the first study dose administration, or anticipated need for the duration of the study.
Sponsor: Neuron23, Inc.
Purpose of the study: To develop a central repository for PD-related genomic data by individuals who consent to deposit their data and bank their residual DNA obtained through clinical genetic testing for future research use.
Eligibility inclusion criteria
- Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson’s disease: probable diagnosis based on Investigator discretion.
- Willingness to undergo genetic testing and may choose to be informed of genetic test results for, at minimum, seven Parkinsons-related genes, including: GBA1, LRRK2, SNCA, VPS35, PRKN, PINK1, PARK7. Participants may choose to also receive additional findings which might be related to their PD diagnosis and/or health-related clinically actionable findings.
Eligibility exclusion criteria
- Probable diagnosis at the time of consent of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
- Individuals who have received a blood transfusion within the past 3 months.
- Individuals who have active hematologic malignancies such as lymphoma or leukemia.
- Individuals who have had a bone marrow transplant within the past 5 years.
Sponsor: Parkinson's Foundation
Other Conditions
Purpose of Study: The objective of this prospective, multisite, single-arm study is to capture the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor in patients with essential tremor (ET).
Description of Study: This study is evaluating a new technique for performing thalamotomy for tremor control. While current techniques have possible invasive or radiation effects, the use of ExAblate is non-invasive and without radiation. After informed consent and screening, eligible subjects will undergo an ExAblate treatment. All subjects will be followed at one day; one week; one, three, six and 12 months; and for up to five years as directed by their doctor.
Eligibility Criteria: Men and women age 22 and older with a diagnosis of essential tremor, as confirmed by clinical history and examination by a neurologist or neurosurgeon specialized in movement disorder, and significant disability from their ET despite medical treatment. Subjects should be on a stable dose of all ET medications for 30 days prior to study entry, able to communicate sensations during the ExAblate transcranial procedure, and able and willing to give informed consent and attend all study visits.
Status of Study: Recruiting
Contacts:
Phuong (Lina) Nguyen, MBA, CCRP
Phone: 614-366-6952
Email: phuong.nguyen2@osumc.edu
Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu
Sponsor: Insightec